{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:52Z","timestamp":1787009452953,"version":"build-2736575974"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases at the National Institutes of Health","award":["R03AI132801"],"award-info":[{"award-number":["R03AI132801"]}]},{"name":"National Institute of Allergy and Infectious Diseases at the National Institutes of Health","award":["U54GM115677"],"award-info":[{"award-number":["U54GM115677"]}]},{"name":"National Institute of General Medical Sciences of the National Institutes of Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Experiments in vitro have shown that the drug amodiaquine may inhibit Ebola virus activity. During the Ebola virus disease (EVD) epidemic in West Africa in 2014\u20132016, 2 mass drug administrations (MDAs) of artesunate-amodiaquine (ASAQ) were implemented to decrease the burden of malaria. The objective of this study was to assess the effect of the ASAQ MDAs on the mortality of patients with EVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort design was used to analyze mortality data for patients with EVD admitted to 5 Ebola treatment units in Liberia and Sierra Leone. Patients admitted to the ETUs during the time period of ASAQ\u2019s therapeutic effect from areas where the MDA was implemented were matched to controls not exposed to ASAQ, using a range of covariates, including malaria co-infection status, and a logistic regression analysis was performed. The primary outcome was Ebola treatment unit mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 424 patients with EVD had sufficient data for analysis. Overall, the mortality of EVD patients was 57.5%. A total of 22 EVD patients were exposed to ASAQ during the MDAs and were found to have decreased risk of death compared with those not exposed in a matched analysis, but this did not reach statistical significance (relative risk, 0.63; 95% confidence interval, 0.37\u20131.07; P = .086).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There was a non\u2013statistically significantly decreased risk of mortality in EVD patients exposed to ASAQ during the 2 MDAs as compared with EVD patients not exposed to ASAQ. Further prospective trials are needed to determine the direct effect of ASAQ on EVD mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofz250","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T11:18:36Z","timestamp":1558696716000},"source":"Crossref","is-referenced-by-count":11,"title":["Effect of Mass Artesunate-Amodiaquine Distribution on Mortality of Patients With Ebola Virus Disease During West African Outbreak"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0919-2841","authenticated-orcid":false,"given":"Stephanie C","family":"Garbern","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick","family":"Yam","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Center for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam R","family":"Aluisio","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel K","family":"Cho","sequence":"additional","affiliation":[{"name":"Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Ministry of Health, Monrovia, Liberia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6732-5422","authenticated-orcid":false,"given":"Moses","family":"Massaquoi","sequence":"additional","affiliation":[{"name":"Ministry of Health, Monrovia, Liberia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foday","family":"Sahr","sequence":"additional","affiliation":[{"name":"Sierra Leone Ministry of Defense, Freetown, Sierra Leone"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiromi M","family":"Perera","sequence":"additional","affiliation":[{"name":"International Medical Corps, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C","family":"Levine","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Center for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,24]]},"reference":[{"key":"2020081003573334900_CIT0001","author":"World Health Organization","year":"2016"},{"key":"2020081003573334900_CIT0002","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/cid\/ciw601","article-title":"Resurgence of Ebola virus disease in guinea linked to a survivor with virus persistence in seminal fluid for more than 500 days","volume":"63","author":"Diallo","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020081003573334900_CIT0003","author":"World Health Organization"},{"key":"2020081003573334900_CIT0004","author":"World Health Organization"},{"key":"2020081003573334900_CIT0005","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"A randomized, controlled trial of ZMapp for Ebola virus infection","volume":"375","author":"PREVAIL II Writing Group","year":"2016","journal-title":"New England J Med"},{"key":"2020081003573334900_CIT0006","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","article-title":"Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia","volume":"377","author":"Kennedy","year":"2017","journal-title":"N Engl J Med"},{"key":"2020081003573334900_CIT0007","doi-asserted-by":"crossref","first-page":"13476","DOI":"10.1038\/srep13476","article-title":"Identification of agents effective against multiple toxins and viruses by host-oriented cell targeting","volume":"5","author":"Zilbermintz","year":"2015","journal-title":"Sci Rep"},{"key":"2020081003573334900_CIT0008","doi-asserted-by":"crossref","first-page":"277","DOI":"10.12688\/f1000research.5741.1","article-title":"A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus","volume":"3","author":"Ekins","year":"2014","journal-title":"F1000Res"},{"key":"2020081003573334900_CIT0009","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.antiviral.2018.10.025","article-title":"Novel amodiaquine derivatives potently inhibit Ebola virus infection","volume":"160","author":"Sakurai","year":"2018","journal-title":"Antiviral Res"},{"key":"2020081003573334900_CIT0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504605","article-title":"Effect of artesunate-amodiaquine on mortality related to Ebola virus disease","volume":"374","author":"Gignoux","year":"2016","journal-title":"N Engl J Med"},{"key":"2020081003573334900_CIT0011","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12936-016-1493-1","article-title":"Impact of the mass drug administration for malaria in response to the Ebola outbreak in Sierra Leone","volume":"15","author":"Aregawi","year":"2016","journal-title":"Malar J"},{"key":"2020081003573334900_CIT0012","doi-asserted-by":"crossref","first-page":"394","DOI":"10.9745\/GHSP-D-16-00186","article-title":"Successful implementation of a multicountry clinical surveillance and data collection system for Ebola virus disease in West Africa: findings and lessons learned","volume":"4","author":"Roshania","year":"2016","journal-title":"Glob Health Sci Pract"},{"key":"2020081003573334900_CIT0013","volume-title":"Clinical management of patients with viral haemorrhagic fever: a pocket guide for front-line health workers: interim emergency guidance for country adaptation","author":"World Health Organization","year":"2016"},{"key":"2020081003573334900_CIT0014","volume-title":"Filovirus haemorrhagic fever guidelines","author":"Medicins Sans Frontieres","year":"2008"},{"key":"2020081003573334900_CIT0015","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/1475-2875-8-200","article-title":"Population pharmacokinetics of artesunate and amodiaquine in African children","volume":"8","author":"Stepniewska","year":"2009","journal-title":"Malar J"},{"key":"2020081003573334900_CIT0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: a review and a look forward","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci"},{"key":"2020081003573334900_CIT0017","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1473-3099(17)30112-3","article-title":"Characteristics and survival of patients with Ebola virus infection, malaria, or both in Sierra Leone: a retrospective cohort study","volume":"17","author":"Waxman","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2020081003573334900_CIT0018","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1056\/NEJMsr1513109","article-title":"After Ebola in West Africa\u2014unpredictable risks, preventable epidemics","volume":"375","author":"WHO Ebola Response Team","year":"2016","journal-title":"New England J Med"},{"key":"2020081003573334900_CIT0019","doi-asserted-by":"crossref","first-page":"20160308","DOI":"10.1098\/rstb.2016.0308","article-title":"Heterogeneities in the case fatality ratio in the West African Ebola outbreak 2013\u20132016","volume":"372","author":"Garske","year":"2017","journal-title":"Phil Trans R Soc B"},{"key":"2020081003573334900_CIT0020","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/sim.4200","article-title":"Comparing paired vs non-paired statistical methods of analyses when making inferences about absolute risk reductions in propensity-score matched samples","volume":"30","author":"Austin","year":"2011","journal-title":"Stat Med"},{"key":"2020081003573334900_CIT0021","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-3156.2004.01367.x","article-title":"Evidence basis for antimalarial policy change in Sierra Leone: five in vivo efficacy studies of chloroquine, sulphadoxine-pyrimethamine and amodiaquine","volume":"10","author":"Checchi","year":"2005","journal-title":"Trop Med Int Health"},{"key":"2020081003573334900_CIT0022","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12936-018-2371-9","article-title":"How long do rapid diagnostic tests remain positive after anti-malarial treatment?","volume":"17","author":"Dalrymple","year":"2018","journal-title":"Malar J"},{"key":"2020081003573334900_CIT0023","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/s12936-016-1529-6","article-title":"Performance and time to become negative after treatment of three malaria rapid diagnostic tests in low and high malaria transmission settings","volume":"15","author":"Grandesso","year":"2016","journal-title":"Malar J"},{"key":"2020081003573334900_CIT0024","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41256-016-0005-8","article-title":"Determinants of patient survival during the 2014 Ebola virus disease outbreak in Bong County, Liberia","volume":"1","author":"Weppelmann","year":"2016","journal-title":"Glob Health Res Policy"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofz250\/28701594\/ofz250.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/7\/ofz250\/33589968\/ofz250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/7\/ofz250\/33589968\/ofz250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T09:08:37Z","timestamp":1608023317000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofz250\/5498323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,24]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofz250","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,5,24]]},"article-number":"ofz250"}}